An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors

European Journal of Neurology

Volumn 7, Issue 2, 2000, Pages 159-169

  Kumar, V ^a   Anand, R ^b   Messina, J ^b   Hartman, R ^b   Veach, J ^b  

^a Florida Institute of Neurosciences and Clinical Research   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Rivastigmine; Vascular risk factors

Indexed keywords

PLACEBO; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0034463115     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2000.00046.x     Document Type: Article

References (45)

1. Pentoxifylline in cerebrovascular dementia
2. Brain neurotransmitters in aging and dementia: Similar changes across diagnostic dementia groups
3. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
4. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
5. Measurement of quality-of-life changes in patients with Alzheimer's disease
6. Therapeutic results with nimodipine in primary degenerative dementia and multi-infarct dementia
7. 'Mini-Mental State.' A practical method for grading the cognitive status of patients for the clinician
8. The consortium to establish a registry for Alzheimer's disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease
9. Butyrylcholinesterase in the life cycle of amyloid plaques
10. Cerebral blood flow in dementia
11. Polypharmacy in the elderly: Clinical implications
12. Clinical neuropathological findings in multi-infarct dementia: A report of six autopsied cases
13. HWA 285 for the treatment of dementia - Results of a 12 month clinical trial
14. Pharmacological approaches in the treatment of senile dementia
15. Improved cognition after control of risk factors for multi-infarct dementia
16. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
17. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
18. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention, and treatment
19. Vascular disease and dementia in the elderly
20. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
21. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology
22. The Global Deterioration Scale for assessment of primary degenerative dementia
23. Clinical global measure of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
24. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment
25. Decreased cerebral blood flow precedes multiinfarct dementia, but follows ,senile dementia of the Alzheimer type
26. A new rating scale for Alzheimer's disease
27. Pathological verification of ischemic score in differentiation of dementias
28. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
29. Inhibition of acetylcholinesterase modulates the autoregulation of cerebral blood flow and attenuates ischemic brain metabolism in hypertensive rats
30. Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia
31. A systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease
32. Overview of clinical trials of hydergine in dementia
33. Brain infarction and the clinical expression of Alzheimer's disease: The Nun Study
34. Postischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus
35. Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain
36. Chronic administration of acetylcholinesterase inhibitor in the senescent rat brain
37. Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia
38. Dementia associated with cerebrovascular disease, other degenerative diseases, and metabolic disorders
39. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswager and multiple small infarct types as compared with Alzheimer-type dementia
40. Observations of the brains of demented old people
41. The effect of acetylcholinesterase inhibitor (SDZ ENA 713) for r-CBF and focal cerebral ischaemia
42. The clinical diagnosis of Alzheimer's disease
43. Plasma and serum G4 isoenzyme of acetylcholinesterase in patients with Alzheimer-type dementia and vascular dementia